Acceptability of Hepatitis B Vaccination in General Population (PopCorn)

GlaxoSmithKline (GSK) logo

GlaxoSmithKline (GSK)

Status

Completed

Conditions

Hepatitis B

Treatments

Other: Data collection

Study type

Observational

Funder types

Industry

Identifiers

NCT01782794
113269

Details and patient eligibility

About

The present study is conducted in order to assess the acceptability of Hepatitis B vaccination in French general population before and after reimbursement of the paediatric vaccine InfanrixHexa. Four measurements are planned, first before reimbursement and the others at year 1, 2 and 3 after reimbursement.

Full description

The present study aims to evaluate the changes in Hepatitis B immunization coverage and the acceptability thereof among parents, in the general population. This is a national, prospective, epidemiological study, comprising four measurement time-points over a three-year period, (T1 in 2009, T2 in 2010, T3 in 2011, and T4 in 2012) in order to cover the period prior to the introduction of InfanrixHexa® reimbursement, the transition period, and the period following reimbursement of the vaccine. The periods between each data collection time-point will be identical, lasting a year. Two age groups will be investigated at each data collection time-point: 12-15 months and 24-27 months, thus providing measurements before/after reimbursement.

Enrollment

2,413 patients

Sex

All

Ages

12 to 27 months old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Infants aged 12 to 15 months or 24 to 27 months inclusive at the time of the study.
  • With a parent or legal representative agreeing to take part in the interview.
  • Residing in metropolitan France.

Exclusion criteria

  • Refusal to take part.
  • Infants having lived in another country in their first two years of life.

Trial design

2,413 participants in 2 patient groups

Cohort A
Description:
Children aged 12-15 months at the time of the study. Measurements of Hepatitis B vaccination cover prior to InfanrixHexa reimbursement was obtained from this cohort.
Treatment:
Other: Data collection
Cohort B
Description:
Children aged 24-27 months at the time of the study. Measurements of Hepatitis B vaccination cover prior to InfanrixHexa reimbursement was obtained from this cohort.
Treatment:
Other: Data collection

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems